WACKER BIOSOLUTIONS

In 2018, WACKER BIOSOLUTIONS lifted its sales by 10.0 percent to €227.0 million (2017: €205.9 million). The increase was mainly driven by volume growth and better prices for some products. The biggest sales gains were posted by pharmaceutical proteins and by the Pharma/Agro business line. In regional terms, sales performance was particularly positive in Germany and the Americas.

At €23.5 million, decreased significantly year over year (2017: €37.5 million). This was primarily due to higher raw-material costs, to integration costs for the new sites in León and Amsterdam, and to still-low utilization rates at the new biologics production plant in the Netherlands. The EBITDA margin was 10.4 percent (2017: 18.2 percent).

Capital expenditures climbed year over year to €17.9 million (2017: €15.7 million), a rise of 14.0 percent. Investments focused on expansion and modernization projects at the plants in León (Spain) and Jena (Germany). In addition, in April 2018, we acquired a biopharmaceuticals production site in Amsterdam from SynCo Bio Partners Luxembourg S. à. r. l. The capacity of the two lines there is 1,800 liters. As a result, WACKER BIOSOLUTIONS doubled its total production capacity for biopharmaceuticals. Due to the acquisition, employee numbers rose to 709 as of December 31, 2018 (Dec. 31, 2017: 533).

 (XLS:) Download XLS
Key Data: WACKER BIOSOLUTIONS

 

 

 

 

 

€ million

 

2018

 

2017

 

20161

 

2015

 

2014

1

Costs from selling expenses reclassified to R&D expenses as of 2016

 

 

 

 

 

 

 

 

 

 

 

Total sales

 

227.0

 

205.9

 

206.4

 

197.1

 

176.2

EBITDA

 

23.5

 

37.5

 

37.0

 

32.2

 

23.6

EBITDA margin (%)

 

10.4

 

18.2

 

17.9

 

16.3

 

13.4

EBIT

 

9.8

 

26.1

 

25.7

 

21.0

 

13.6

Capital expenditures

 

17.9

 

15.7

 

9.1

 

6.2

 

8.4

R&D expenses

 

6.3

 

6.0

 

6.2

 

6.1

 

6.7

Employees (December 31, number)

 

709

 

533

 

510

 

491

 

484

EBITDA
Earnings before interest, taxes, depreciation and amortization.
Fermentation
In biotechnology, fermentation means the conversion of biological materials by means of bacterial, fungal and cell cultures, or by the addition of enzymes. For example, products such as insulin, many different antibiotics and amino acids (e.g. cysteine) can be synthesized on an industrial scale in bioreactors using microorganisms.

todo Vorjahresvergleich